CareDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high-value, non-invasive surveillance solutions for transplant recipients, has entered into a definitive agreement to acquire ImmuMetrix, Inc., a privately held Palo Alto, California-based development-stage transplant diagnostics company founded by Stephen Quake, PhD, with R&D programs and intellectual property in cell-free DNA. The acquisition is scheduled to close by the end of the second quarter of this year.
ImmuMetrix’ contributions in the field of genomics include single cell gene expression and genome sequencing, non-invasive tests for heart transplant rejection, and the development of approaches to sequence and analyze an individual's immune system.
“We believe that this acquisition will further strengthen our position in organ transplant surveillance, for both our current indication in heart with AlloMap and with other organs in our pipeline,” says Peter Maag, President and CEO of CareDx. “Dr. Quake has an impressive background in genomics research and is a successful entrepreneur, having founded several highly successful diagnostics companies in the Bay Area. We are proud to have him support CareDx and our efforts to develop more products to help transplant recipients and their healthcare providers achieve better clinical outcomes.”
“The combination of innovative cell-free DNA technology from ImmuMetrix with the strong commercial channel provided by CareDx will result in a new generation of diagnostic products to improve the care and treatment of transplant patients,” says Stephen Fodor, PhD, a member of the Board of Directors of ImmuMetrix. Read more about CareDx and the AlloMap gene expression test.
Read more
